Nabi Biopharmaceuticals (NASDAQ:NABI)
CAPS Rating:
The Company leverage its experience and knowledge in powering the human immune system to develop and market products that target serious medical conditions in the areas of transplantation, infectious disease and hematology/oncology.
RSS Headlines
Fool UK
Recs
"Data from this second [failed] trial may provide clues that could help explain the disappointing results from the first trial,"Lolz!There's nothing left. No coming back from this. their only product in trials doesn't work. At all.